Кардиоваскулярные и метаболические проблемы при применении ингибиторов тирозинкиназ 2-го поколения у пациентов с хроническим миелолейкозом
https://doi.org/10.17650/1818-8346-2015-10-3-58-63
Аннотация
При терапии ингибитором тирозинкиназ 2-го поколения хронического миелолейкоза у ряда пациентов наблюдается различной степени негематологическая токсичность. В статье приведен литературный обзор влияния ингибиторов тирозинкиназ 2-го поколения на частоту развития проблем со стороны сердечно-сосудистой системы, углеводного и липидного обмена.
Об авторе
Ольга Юрьевна Виноградова
ФГБУ «Федеральный научно-клинический центр детской гематологии, онкологии и иммунологии им. Д. Рогачева» Минздрава России;
ГБОУ ВПО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России
Россия
Россия
117198, Москва, ул. Саморы Машела, 1;
117997, Москва, ул. Островитянова, 1
Список литературы
1. Воробьев А.И., Абдулкадыров К.М., Хорошко Н.Д. Диагностика и терапия хронического миелолейкоза. М., 2011. 53 с. [Vorobiyov A.I., Abdulkadyrov K.M., Khoroshko N.D. Diagnostics and therapy of chronic myeloid leukemia. Moscow, 2011. 53 p. (In Russ.)].
2. Абдулкадыров К.М., Туркина А.Г., Хороршко Н.Д. Федеральные клинические рекомендации по диагностике и терапии хронического миелолейкоза, Вестник гематологии 2013;9(3). [Abdulkadyrov K.M., Turkina A.G., Khoroshko N.D. Federal clinical recommendations regarding diagnostics and therapy of chronic myeloid leukemia. Vestnik Gematologii = Hematology Herald 2013;9(3). (In Russ.)].
3. Виноградова О.Ю., Куликов С.М., Куцев С.М. и др. Проблемы организации лечения хронического миелолейкоза в России. Клиническая онкогематология 2011;4:23–7. [Vinogradova O.Y., Kulikov S.M., Kutsev S.M. et al. Problems of arrangement of therapy of chronic myeloid leukemia in Russia. Klinicheskaya Onkogematologiya = Clinical Oncohematology 2011;4:23–7. (In Russ.)].
4. Le Coutre P., Ottmann O.G., Giles F. et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood 2008;111(4):1834–9.
5. Mauro M., Cervantes F., Lipton J.H. et al. Dasatinib 2-year efficacy in patients with chronic- phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C). J Clin Oncol 2008;26(15S (May 20 Supplement)):1.
6. Saglio G., Kim DW., Issaragrisil S. et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362:2251–9.
7. Kantarjian H., Shah N.P., Hochhaus A. et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010;362:2260–70.
8. NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia. Version 1.2015. Fort Washington, PA: National Comprehensive Cancer Network, 2015. Available from: www.nccn.org/professionals/physician_gls/pdf/cml.pdf [Last accessed 31 March 2015].
9. Baccarani M., Deininger M.W., Rosti G. et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013;122:872–84.
10. Radivoyevitch T., Hlatky L., Landaw J., Sachs R.K. Quantitative modeling of chronic myeloid leukemia: insights from radiobiology. Blood. 2012;119(19):4363–71.
11. Куликов С.М., Виноградова О.Ю., Челышева Е.Ю. и др. Заболеваемость хроническим миелолейкозом в 6 регионах России по данным популяционного исследования 2009–2012 гг. Терапевтический архив 2014;7:27–32. [Kulikov S.M., Vinogradova O.Yu., Chelysheva E.Yu. et al. Incidence rate of chronic myeloid leukemia in 6 regions of Russia according to the data of the population study in 2009 to 2012. Terapevticheskiy arkhiv = Therapeutical Archive 2014;7:27–32. (In Russ.)].
12. Jabbour E., Makenbaeva D., LingohrSmith M., Lin J. Evaluation of comorbidities relevant to tyrosine kinase inhibitor treatment among patients with chronic myelogenous leukemia in the U.S. Managed care setting, december. Blood 2014;6(21):24.
13. Zdenek R., Belohlavkova P., Cetkovsky P. et al. Comparison of glucose and lipid metabolism abnormality during nilotinib, imatinib and dasatinib therapy – results of Enigma 2 study. Blood 2014;124(21):1813.
14. Ito Y., Miyamoto T., Chong Y. et al. Nilotinib exacerbates diabetes mellitus by decreasing secretion of endogenous insulin. Int J Hematol 2013;97:(1);135–8.
15. Kim T.D., Rea D., Schwarz M. et al. Peripheral arteryocclusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib. Leukemia 2013;27:1316–21.
16. Breccia M., Muscaritoli M., Cannella L. et al. Fasting glucose improvement under dasatinib treatment in an accelerated phase chronic myeloid leukemia patient unresponsive to imatinib and nilotinib. Leuk Res 2008;32(10):1626–8.
17. Saglio G., Kim D.W., Issaragrisil S. et al. ENESTnd Investigators. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362(24):2251–9.
18. Kantarjian H.M., Hochhaus A., Saglio G. et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-upof the phase 3 randomised ENESTnd trial.
19. Lancet Oncol. 2011;12(9):841-51.
20. Larson R.A., Hochhaus A., Hughes T.P. et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosomepositive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia 2012;26(10):2197–203.
21. Rea D., Gaultier J., Breccia M. et al. Incidence of hyperglycemia by 3 years inpatients with newly diagnosed chronic myeloid leukemia in chronic phase(CMLCP) treated with nilotinib or imatinib in ENESTnd. Blood 2012;120: abstract 1686.
22. Agostino N.M., Chinchilli V.M., Lynch C.J. et al. Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice. J Oncol Pharm Pract 2011;17(3):197–202.
23. Breccia M., Muscaritoli M., Cannella L. et al. Fasting glucose improvement under dasatinib treatment in an accelerated phase chronic myeloid leukemia patient unresponsive to imatinib and nilotinib. Leuk Res. 2008;32(10):1626–8.
24. Ono K., Suzushima H., Watanabe Y. et al. Rapid amelioration of hyperglycemia facilitated by dasatinib in a chronic myeloid leukemia patient with type 2 diabetes mellitus. Intern Med 2012;51(19):2763–6.
25. Cheng H., Straub S.G., Sharp G.W. Inhibitory role of Src family tyrosine kinases on Ca2+-dependent insulin release. Am J Physiol Endocrinol Metab. 2007;292(3):E845–52.
26. Hiwase D.K., Yeung D.T., Carne L. et al. Hypercholesterolemia in imatinib intoler-ant/ resistant CML-CP patients treated with nilotinib: a retrospective analysis. Blood 2013;122:1503.
27. Rea D., Mirault T., Gaultier J.F. et al. Prospective analysis of plasma cholesterol and triglycerides in patients with chronic phase-chronic myeloid leukemia during treatment with the 2nd generation tyrosine kinase inhibitor nilotinib. Blood 2013;122:4042.
28. Aichberger K.J., Herndlhofer S., Schernthaner G.H. et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol 2011;86(7):533–9.
29. Le Coutre P., Rea D., Abruzzese E. et al. Severe peripheral arterial disease during nilotinib therapy. J Natl Cancer Inst 2011;103(17):1347–8.
30. Kim T.D., Rea D., Schwarz M. et al. Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib. Leukemia 2013;27(6):1316–21.
31. Levato L., Cantaffa R., Kropp M.G. et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in chronic myeloid leukemia: a single institution study. Eur J Haematol 2013;90(6):531–2.
32. Mirault T., Rea D., Azarine A., Messas E. Rapid onset of peripheral artery disease in a chronic myeloid leukemia patient without prior arterial disorder: direct relationship with nilotinib exposure and clinical outcome Eur J Haematol 2015;94(4):363–7.
33. Valent P., Hadzijusufovic E., Schernthaner G. et al. Vascular safety issues in CML patients
34. treated with BCR/ABL1 kinase inhibitors. Blood 2015;125(6):901–6.
35. Gilbert J. et al. Incidence of vascular thrombotic events in 183 consecutive patients treated with nilotinib: a single centre experience. Blood 2014;124(21).
36. Final study results of the phase 3 dasatinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase (CMLCP) Trial (DASISION, CA180-056). Blood 2014;124:abstract 152.
37. Montani D., Bergot E., Günther S. et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 2012;125(17):2128–37.
38. Rasheed W., Flaim B., Seymour J.F. Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia. Leuk Res 2009;33(6):861–4.
39. Montani D., Bergot E., Gunther S. et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 2012;125(17):2128–37.
40. Sano M., Saotome M., Urushida T. et al. Pulmonary arterial hypertension caused by treatment with dasatinib for chronic myeloid leukemia -critical alert-. Intern Med 2012;51(17):2337–40.
41. Mattei D., Feola M., Orzan F. et al. Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient. Bone Marrow Transplant 2009;43(12):967–8.
42. Hennigs J.K., Keller G., Baumann H.J. et al. Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension. BMC Pulm Med 2011;11:30.
43. Dumitrescu D., Seck C., ten Freyhaus H. et al. Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia. Eur Respir J 2011;38(1):218–20.
44. Orlandi E.M., Rocca B., Pazzano A.S. et al. Reversible pulmonary arterial hypertension likely related to long-term, low-dose dasatinib treatment for chronic myeloid leukaemia. Leuk Res 2012;36(1):4–6.
45. Giuseppe S. The observed and expected incidence of cardiovascular ischemic events in dasatinib-treated patients across a clinical trial program. ASH 2014. Poster 4534.
46. Cortes J. Cardiovascular and pulmonary adverse events in patients treated with BCRABL inhibitors: data from the FDA Adverse Event Reporting System, Am J Hematol 2015;90(4):E66–72.
47. Breccia M., Molica M., Zacheo I. et al. Application of systematic coronary risk evaluation chart to identify chronic myeloid leukemia patients at risk of cardiovascular diseases during nilotinib treatment. Ann Hematol 2015;94(3):393–7.
48. Инструкция по медицинскому применению лекарственного препарата Тасигна. [Instruction for medical application of Tasigna. (In Russ.)].
49. Инструкция по медицинскому применению лекарственного препарата Cпрайсел. [Instruction for medical application of Sprycell. (In Russ.)].
Рецензия
Для цитирования:
Виноградова О.Ю. Кардиоваскулярные и метаболические проблемы при применении ингибиторов тирозинкиназ 2-го поколения у пациентов с хроническим миелолейкозом. Онкогематология. 2015;10(3):58-63. https://doi.org/10.17650/1818-8346-2015-10-3-58-63
For citation:
Vinogradova O.Y. Cardiovascular and metabolic problems associated with application of second generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Oncohematology. 2015;10(3):58-63. (In Russ.) https://doi.org/10.17650/1818-8346-2015-10-3-58-63
Просмотров:
9679
Послать статью по эл. почте 